Truist reiterates Salesforce stock Buy rating after developer event By Investing.com

Truist Securities reiterated a Buy rating on Salesforce with a $280 price target, implying about 54% upside from the cited $181.32 share price. The firm said TDX customer feedback was constructive: Salesforce Flow was well received, Agentforce pricing remains a friction point, and LLM-based agentic coding tools are not displacing Salesforce. The tone is positive for CRM fundamentals and 2026 adoption prospects, but the update is still mainly analyst commentary rather than a near-term catalyst.

Analysis

CRM is reading as a classic “good enough fundamentals, improving narrative” setup: the core product is not being displaced, but the market still wants proof that the AI layer can monetize without choking adoption. That matters because if pricing friction eases, the next leg of multiple expansion can come from lower sales-cycle resistance rather than a step-change in product capability. In other words, the upside is less about dramatic beat-and-raise and more about removing the biggest obstacle to enterprise AI conversion.

The second-order winner is not necessarily CRM alone; it is the adjacent automation stack. If Salesforce makes agent pricing cleaner and Flow remains the default orchestration layer, that raises switching costs across middleware, low-code, and workflow vendors, while making point AI tools more likely to get absorbed into the platform rather than sold standalone. PATH is the most obvious relative loser if enterprise buyers decide to consolidate automation spend into incumbent platforms instead of buying best-of-breed robotic process automation.

The key risk is timing: this is a 6-18 month adoption story, not a next-quarter catalyst. If pricing remains ambiguous into the next budget cycle, buyers may defer Agentforce experiments and stick with pilot-sized deployments, which would cap near-term ARR acceleration even if sentiment stays constructive. Conversely, a clear packaging change or evidence of higher agent attach rates in fiscal 2026 could force a re-rating quickly because the market is currently underweighting the monetization optionality.

The contrarian view is that consensus may be overfocusing on displacement risk and underestimating platform consolidation. LLM-native coding tools can coexist with CRM if they improve productivity at the edge while Salesforce owns workflow, identity, and governance. That makes CRM less of a “product threatened by AI” story and more of a “distribution and pricing architecture” story, which typically resolves in favor of the incumbent once procurement standardization begins.

Key Decisions for Investors

• Long CRM vs. short PATH as a 3-6 month relative-value trade: CRM benefits if enterprise AI spend consolidates inside incumbent workflow platforms; PATH is more exposed to budget reallocation and pricing pressure.
• Buy CRM on pullbacks into the next earnings window with a 6-12 month horizon; risk/reward improves if management signals cleaner Agentforce packaging, because small pricing changes can drive outsized multiple expansion.
• Use CRM call spreads for a defined-risk upside expression over the next 2-3 quarters; the setup is a rerating trade, not a deep fundamental re-acceleration trade, so convexity is preferable to outright stock risk.
• Avoid chasing the move if CRM trades purely on analyst enthusiasm without evidence of attach-rate or pricing improvement; the downside is a sentiment fade rather than a fundamental break, but that can compress multiple quickly.
• Watch PATH and other automation names for spillover weakness if Salesforce’s agentic workflow story gains traction; if that happens, rotate toward incumbent platform beneficiaries rather than standalone automation vendors.